Dependency of Tamoxifen Sensitive and Resistant ER+ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth

被引:3
|
作者
Bhasin, Satyam [1 ,2 ]
Dusek, Christopher [1 ,2 ]
Peacock, James W. [1 ,2 ]
Cherkasov, Artem [1 ,2 ]
Wang, Yuzhuo [1 ,2 ]
Gleave, Martin [1 ,2 ]
Ong, Christopher J. [1 ,2 ]
机构
[1] Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada
[2] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada
关键词
ER+ breast cancer; Semaphorin; 3C; plexin-B1; siRNA knockdown; Akt-MAPK signaling; apoptosis; B1SP; tamoxifen-resistance; EXPRESSION; MECHANISMS; IMPACT;
D O I
10.3390/cells12131715
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Estrogen receptor positive (ER+) breast cancer (BCa) accounts for the highest proportion of breast cancer-related deaths. While endocrine therapy is highly effective for this subpopulation, endocrine resistance remains a major challenge and the identification of novel targets is urgently needed. Previously, we have shown that Semaphorin 3C (SEMA3C) is an autocrine growth factor that drives the growth and treatment resistance of various cancers, but its role in breast cancer progression and endocrine resistance is poorly understood. Here, we report that SEMA3C plays a role in maintaining the growth of ER+ BCa cells and is a novel, tractable therapeutic target for the treatment of ER+ BCa patients. Analyses of publicly available clinical datasets indicate that ER+ BCa patients express significantly higher levels of SEMA3C mRNA than other subtypes. Furthermore, SEMA3C mRNA expression was positively correlated with ESR1 mRNA expression. ER+ BCa cell lines (MCF7 and T47D) expressed higher levels of SEMA3C mRNA and protein than a normal mammary epithelial MCF10A cell line. ER siRNA knockdown was suppressed, while dose-dependent beta-estradiol treatment induced SEMA3C expression in both MCF7 and T47D cells, suggesting that SEMA3C is an ER-regulated gene. The stimulation of ER+ BCa cells with recombinant SEMA3C activated MAPK and AKT signaling in a dose-dependent manner. Conversely, SEMA3C silencing inhibited Estrogen Receptor (ER) expression, MAPK and AKT signaling pathways while simultaneously inducing apoptosis, as monitored by flow cytometry and Western blot analyses. SEMA3C silencing significantly inhibited the growth of ER+ BCa cells, implicating a growth dependency of ER+ BCa cells on SEMA3C. Moreover, the analysis of tamoxifen resistant (TamR) cell models (TamC3 and TamR3) showed that SEMA3C levels remain high despite treatment with tamoxifen. Tamoxifen-resistant cells remained dependent on SEMA3C for growth and survival. Treatment with B1SP Fc fusion protein, a SEMA3C pathway inhibitor, attenuated SEMA3C-induced signaling and growth across a panel of tamoxifen sensitive and resistant ER+ breast cancer cells. Furthermore, SEMA3C silencing and B1SP treatment were associated with decreased EGFR signaling in TamR cells. Here, our study implicates SEMA3C in a functional role in ER+ breast cancer signaling and growth that suggests ER+ BCa patients may benefit from SEMA3C-targeted therapy.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
    Peacock, James W.
    Takeuchi, Ario
    Hayashi, Norihiro
    Liu, Liangliang
    Tam, Kevin J.
    Al Nakouzi, Nader
    Khazamipour, Nastaran
    Tombe, Tabitha
    Dejima, Takashi
    Lee, Kevin C. K.
    Shiota, Masaki
    Thaper, Daksh
    Lee, Wilson C. W.
    Hui, Daniel H. F.
    Kuruma, Hidetoshi
    Ivanova, Larissa
    Yenki, Parvin
    Jiao, Ivy Z. F.
    Khosravi, Shahram
    Mui, Alice L-F
    Fazli, Ladan
    Zoubeidi, Amina
    Daugaard, Mads
    Gleave, Martin E.
    Ong, Christopher J.
    EMBO MOLECULAR MEDICINE, 2018, 10 (02) : 219 - 238
  • [22] Semaphorin 3C has a possibility of a new prognostic marker in colorectal cancer
    Kawano, Shingo
    Amemiya, Kota
    Tsuchiya, Yuki
    Hagiwara, Toshiaki
    Matsuzawa, Hirokazu
    Makino, Yurika
    Motegi, Shunsuke
    Tsukamoto, Ryoichi
    Ichikawa, Ryosuke
    Kure, Kazumasa
    Honjo, Kumpei
    Ro, Hisashi
    Ito, Shingo
    Okazawa, Yu
    Takahashi, Rina
    Mizukoshi, Kosuke
    Kawai, Masaya
    Munakata, Shinya
    Niwa, Koichiro
    Ishiyama, Shun
    Sugimoto, Kiichi
    Kamiyama, Hirohiko
    Komiyama, Hiromitsu
    Takahashi, Makoto
    Kojima, Yutaka
    Goto, Michitoshi
    Okuzawa, Atsushi
    Tomiki, Yuichi
    Sakamoto, Kazuhiro
    Kojima, Motohiro
    Ochiai, Atsushi
    CANCER RESEARCH, 2017, 77
  • [23] Semaphorin 3C promotes de novo steroidogenesis in androgen-deprived prostate cancer cells
    Yenki, Parvin
    Adomat, Hans
    Cheng, Chi Wing
    Ong, Christopher
    CANCER RESEARCH, 2016, 76
  • [24] The relationship between semaphorin 3C and microvessel density in the progression of breast and oral neoplasia
    Cole-Healy, Zachary
    Vergani, Patricia
    Hunter, Keith
    Brown, Nicola J.
    Reed, Malcolm W. R.
    Staton, Carolyn A.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2015, 99 (01) : 19 - 24
  • [25] Spatial association of SEMA3C with nerve endings/terminal Schwann cells in hair follicle isthmus region
    Zhong, Hong-Bing
    Chu, Qing-Song
    Xiang, Jan Jian
    Zhang, Arina Li
    Chen, Eve Qian
    Shen, Xing-Ru
    Liao, Xin-Hua
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2020, 80 (08) : 737 - 741
  • [26] Sema3C Promotes the Survival and Tumorigenicity of Glioma Stem Cells through Rac1 Activation
    Man, Jianghong
    Shoemake, Jocelyn
    Zhou, Wenchao
    Fang, Xiaoguang
    Wu, Qiulian
    Rizzo, Anthony
    Prayson, Richard
    Bao, Shideng
    Rich, Jeremy N.
    Yu, Jennifer S.
    CELL REPORTS, 2014, 9 (05): : 1812 - 1826
  • [27] The inhibitory effect of SEMA3C/3D mutations on Neuro-2a cells migration and axonal growth in patients with Hirschsprung′s disease
    Kaihui Yu
    Zhen Zhang
    Qi Li
    Ping Xiao
    Lin Su
    Long Li
    Shangling Pan
    Qian Jiang
    广西医科大学学报, 2017, 34 (08) : 1121 - 1126
  • [28] Protein Kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells
    Lisa B. Frankel
    Anne E. Lykkesfeldt
    Jens B. Hansen
    Jan Stenvang
    Breast Cancer Research and Treatment, 2007, 104 : 165 - 179
  • [29] Protein kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells
    Frankel, Lisa B.
    Lykkesfeldt, Anne E.
    Hansen, Jens B.
    Stenvang, Jan
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 104 (02) : 165 - 179
  • [30] Trastuzumab resistant breast cancer is cross resistant to the FAS inhibitor, C75, but sensitive to tamoxifen.
    Osipo, C.
    Patel, P.
    Lupu, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S247 - S247